A Phase I/II Study of Lenalidomide plus Obinutuzumab and Atezolizumab Immunotherapy in Patients with Recurrent or Persistent Follicular Lymphoma

Full Title

A Phase Ib/II Study Evaluating the Safety and Efficacy of Atezolizumab In Combination With Obinutuzumab Plus Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma

Purpose

The purpose of this study is to assess the safety and effectiveness of different doses of lenalidomide given in combination with obinutuzumab and atezolizumab immunotherapy in patients with follicular lymphoma that has come back or stopped responding to treatment. All three drugs are approved to treat other cancers; their use together in this study is considered investigational.

Atezolizumab is designed to improve the immune system's ability to recognize and destroy cancer cells by blocking PD-L1, a protein made by some cancers that can dampen innate anticancer immune responses. It is approved for treating bladder cancer. Obinutuzumab triggers an immune response against cancer by binding to a target on lymphoma cells called CD20. Obinutuzumab is already approved for treating chronic lymphocytic leukemia, and it is being assessed for the treatment of other cancers, including lymphoma. Both drugs are given intravenously.

Lenalidomide is approved for treating multiple myeloma and myelodysplastic syndromes. It may also help boost the immune response against lymphoma cells. It is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have CD20-positive follicular lymphoma that has come back or stopped responding to therapy that included an anti-CD20 medication.
  • Patients must recover from the serious side effects of prior treatments.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. M. Lia Palomba at 212-639-7186.

Protocol

16-799

Phase

I/II

Investigator

Co-Investigators

Locations